For the year ending 2025-12-31, LCTX made $14,556K in revenue. -$63,533K in net income. Net profit margin of -436.47%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 14,556 | 9,499 | ||
| Cost of royalties | 146 | - | ||
| Research and development | 17,729 | 12,472 | ||
| General and administrative | 18,460 | 18,171 | ||
| Cost of sales | - | 334 | ||
| Loss on impairment of intangible asset (note 6 and note 13) | 14,840 | - | ||
| Total operating expenses | 51,175 | 30,977 | ||
| Loss from operations | -36,619 | -21,478 | ||
| Interest income, net | 1,691 | 1,715 | ||
| Loss on marketable equity securities, net | -8 | -8 | ||
| Change in fair value of warrant liability | 35,727 | -2,128 | ||
| Foreign currency transaction gain (loss), net | 2,148 | -269 | ||
| Other income (expense), net | -132 | -670 | ||
| Total other income (expenses) | -32,028 | 2,896 | ||
| Loss before income taxes | -68,647 | -18,582 | ||
| Income tax benefit | -5,280 | - | ||
| Net loss | -63,367 | -18,582 | ||
| Net (income) loss attributable to noncontrolling interest | 166 | 27 | ||
| Net loss attributable to lineage | -63,533 | -18,609 | ||
| Basic EPS | -0.28 | -0.09 | ||
| Diluted EPS | -0.28 | -0.09 | ||
| Basic Average Shares | 230,116,000 | 200,193,000 | ||
| Diluted Average Shares | 230,116,000 | 200,193,000 | ||
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)